

Kit Contents

ITEM	QUANTITY
Microplate, streptavidin coated, 96 wells	1 plate, 12 x 8 breakable
CALIBRATORS	Lyophilised
NSE A	1 x 0.75 mL
NSE B	1 x 0.75 mL
NSE C	1 x 0.75 mL
NSE D	1 x 0.75 mL
NSE E	1 x 0.75 mL
Biotin Anti-NSE monoclonal antibody	1 x 15 mL
Tracer, HRP Anti-NSE	1 x 0.75 mL
TMB HRP-Substrate	1 x 12 mL
Stop Solution	1 x 15 mL
Wash Concentrate	1 x 50 mL

LITERATURE REFERENCES

1. Paus E. and Nustad K., (1989) Immunoradiometric Assay for $\alpha\gamma$ - and $\gamma\gamma$ -Enolase (Neuron-Specific Enolase), with Use of Monoclonal Antibodies and Magnetizable Polymer Particles. *Clin. Chem.* 35: 2034-2038.
2. Dahlén U., Karlsson B., Nilsson O. and Uhl W., (1995) Development of an Enzyme Immunoassay, NSE-Enzymun Test For Determination of Neuron-Specific Enolase. *XXIII International Society for Oncodevelopmental Biology and Medicine, Montréal, Québec.*
3. Cooper E.H., (1994) Neuron-specific enolase. *The International Journal of Biological Markers* 9(4):205-10.
4. Cooper E.H., Pritchard J., Bailey C.C. and Ninane J., (1987) Serum neuron-specific enolase in children's cancer. *Br. J. Cancer* 56: 65-67.
5. Schneider, P. M. et al., (2002) Lung Cancer. In "Tumor markers, Physiology, Pathobiology, Technology and Clinical Applications" Eds. *Diamandis E. P. et al., AACCC Press, Washington pp 287-303.*
6. Bonner J. A., Sloan JA., Rowland KM., Klee GG., Kugler JW., Mailliard JA., Wiesefeld M., Krook JE., Maksymiuk AW., Shaw EG., Marks RS and Perez EA., (2000) Significance of Neuron-specific Enolase Levels before and during Therapy for Small Cell Lung Cancer. *Clinical Cancer Research* 6: 597-601.
7. Pählman S., Esscher T., Bergvall P. and Odelstad L., (1984) Purification and characterization of human neuron-specific enolase: Radioimmunoassay development. *Tumor Biol.* 5: 127-139.
8. National Committee for Clinical Laboratory Standards, Evaluation of Precision Performance of Clinical Chemistry Devices. *Approved Guideline EP5-A (1999).*
9. National Committee for Clinical Laboratory Standards, National Evaluation Protocols for Interference Testing, *Evaluation protocol Number 7, Vol. 6, No 13, August (1986).*




Fujirebio Diagnostics Inc.
201 Great Valley Parkway
Malvern, PA 19355-1307
USA
+1 610 240 3800 phone
+1 610 240 3803 fax
info@fdi.com e-mail
www.fdi.com website

Fujirebio Diagnostics AB
Majnabbeterminalen
SE-414 55 Göteborg
Sweden
+46 31 85 70 30 phone
+46 31 85 70 40 fax
info@fdab.com e-mail
www.fdab.com website

PRODUCT INFORMATION

CanAg NSE EIA



NSE – Neuron Specific Enolase

Neuron Specific Enolase (NSE) is an enzyme in the glycolytic pathway found in neurons and neuroendocrine cells. Elevated levels are commonly found in patients with malignant tumors with neuro-endocrine differentiation, especially small cell lung cancer (SCLC).

USA:
For Research Use Only
– not for use in diagnostic procedures




Lung cancer

There are 1.2 million new cases of lung cancer annually, the most common cancer worldwide, and it is responsible for 17.8 percent of all cancer deaths*. This disease affects 900,000 men and 330,000 women yearly, and the incidence rates among women continue to increase.

Lung cancer is divided into two major types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC makes up about 20% of all lung cancer cases and is an aggressive form of lung cancer that spreads quickly to other parts of the body.

The CanAg NSE EIA kit is intended for the quantitative determination of neuron specific enolase (NSE) in human serum. NSE levels are low in healthy individuals and in patients with benign diseases, elevated levels are found in patients with neuroendocrine tumors, such as small cell lung cancer (SCLC).

* World Health Organization. www.who.int/mediacentre/news/releases/2003/pr27/en/print.html



Features & Benefits


- Accurate determination around the reference limit 13 µg/L
- One-step EIA assay, results within 2 hours from start of assay
- Streptavidin coated plate

The quantitative determination of NSE in the management of patients with suspected or diagnosed SCLC may be useful in the following areas:

- Differential diagnosis between non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
- Monitoring of therapy response
- Detection of recurrence and metastatic spread
- Prognostic information about survival of patients with lung cancer


Assay procedure

Below is an illustration of the CanAg NSE EIA one-step assay procedure. Results are available within two hours.



CanAg NSE EIA

The CanAg NSE EIA is a one-step sandwich assay in which two monoclonal antibodies (derived from mice) are directed against two separate antigenic determinants on the γ unit of the NSE molecule.



SPECIFICATIONS

Results within:	2 hours, one step procedure
Detection limit:	< 1 µg/L
Measuring range:	1–150 µg/L
Sample volume:	25 µL
Hook effect:	No hook up to 200 000 µg/L
Stability:	18 months at 4° C
Calibrator range:	0–150 µg/L
Incubation temp:	20–25° C
Recovery:	96–109%
Detection:	620 nm or 405 nm
Reference value:	< 13 µg/L

ORDERING INFORMATION

Prod. No. 420-10
 CanAg NSE EIA
 For 96 determinations